Overview

HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis

Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether compared to our standard low dose ATG with CSA, the high dose ATG with low-dose CSA minimizes the chances of relapse and chronic GVHD, without increasing the chances of other transplant complications.
Phase:
Phase 2
Details
Lead Sponsor:
AHS Cancer Control Alberta
Treatments:
Acetaminophen
Antilymphocyte Serum
Cyclosporine
Cyclosporins
Diphenhydramine
Methotrexate
Methylprednisolone
Thymoglobulin